ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08945
-0,01%
Bitcoin
67.182,70
0,15%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Anebulo Pharmaceuticals Inc (ANEB)

  7. Anebulo Pharmaceuticals Inc (ANEB) News

ANEB

Anebulo Pharmaceuticals (ANEB)

Anebulo Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ANEB
DatumZeitQuelleÜberschriftSymbolFirma
15/05/202422h31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANEBAnebulo Pharmaceuticals Inc
15/05/202422h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANEBAnebulo Pharmaceuticals Inc
15/05/202419h05Business WireAnebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
13/02/202422h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANEBAnebulo Pharmaceuticals Inc
13/02/202422h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANEBAnebulo Pharmaceuticals Inc
13/02/202422h05Business WireAnebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
21/11/202322h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANEBAnebulo Pharmaceuticals Inc
14/11/202322h05Business WireAnebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
30/10/202314h31Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ANEBAnebulo Pharmaceuticals Inc
30/10/202314h22Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ANEBAnebulo Pharmaceuticals Inc
19/10/202323h18Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ANEBAnebulo Pharmaceuticals Inc
06/10/202322h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANEBAnebulo Pharmaceuticals Inc
06/10/202322h06Business WireAnebulo Pharmaceuticals Announces New CEONASDAQ:ANEBAnebulo Pharmaceuticals Inc
06/10/202322h06Business WireAnebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of DirectorsNASDAQ:ANEBAnebulo Pharmaceuticals Inc
02/10/202323h01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
22/09/202322h05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ANEBAnebulo Pharmaceuticals Inc
20/09/202322h29Business WireAnebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
20/09/202322h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANEBAnebulo Pharmaceuticals Inc
05/09/202314h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANEBAnebulo Pharmaceuticals Inc
30/08/202314h00Business WireAnebulo Pharmaceuticals to Present at Upcoming Investor and Scientific ConferencesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
21/08/202314h00Business WireAnebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 ExtensionNASDAQ:ANEBAnebulo Pharmaceuticals Inc
11/05/202322h07Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
11/05/202314h16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
11/05/202314h00PR Newswire (US)Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
05/04/202300h33Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
28/03/202314h02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
28/03/202314h00PR Newswire (US)Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid IntoxicationNASDAQ:ANEBAnebulo Pharmaceuticals Inc
08/03/202314h01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
08/03/202314h00PR Newswire (US)Anebulo Pharmaceuticals Expands its Integrated and Outsourced SolutionsNASDAQ:ANEBAnebulo Pharmaceuticals Inc
10/02/202314h38Business Wire Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ANEB

Kürzlich von Ihnen besucht

LSE
0HCB
Alcoa
BMF
DAFQ32K35
DAFQ32K35 - 08/2032
BIT
FLV046
Vontobel
USOTC
TBBC
Triad Business Bank (PK)
UPBT
PTOYBTC
Patientory
LSE
SI55
Bank Nova.23
EU
Y968S
Y968S
BIT
P1YD82
NLBNPIT1YD82 20991231 35...
EU
J829S
J829S
BIT
P1ZKA7
NLBNPIT1ZKA7 20351221 5....
BIT
F05057
Vontobel
LSE
0OBJ
Pbs Finanse
BIT
P20WG2
NLBNPIT20WG2 20241220 26
FX
MDLEUR
MDL vs Euro
COIN
EPCOBTC
USOTC
STEEF
Steer Technologies (QX)
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten